home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 11/19/19

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - CytoDyn's Lead Product Candidate Leronlimab (PRO 140) Inhibits Colon Carcinoma Metastases to Liver and Lung in Preclinical Studies

VANCOUVER, Washington, Nov. 19, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, an...
CYDY - CytoDyn Engages LifeSci Public Relations as Communications Partner

VANCOUVER, Wash., Nov. 18, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced that...

CYDY - CytoDyn Announces Acceptance of Leronlimab (PRO 140) Data for Presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) in March 2020

Independent data from the PRESTIGIO Registry Study Group in Italy shows leronlimab inhibits multi-drug resistant HIV-1 viruses in Heavily Treatment-Experienced (HTE) patients VANCOUVER, Washington, Nov. 18, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn”...

CYDY - CytoDyn Appoints New Chief Financial Officer

VANCOUVER, Washington, Nov. 14, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, an...
CYDY - CytoDyn to Present at Wall Street Reporter's "NEXT SUPER STOCK Live" Conference on November 14, 2019

VANCOUVER, Washington, Nov. 13, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...

CYDY - CytoDyn Receives IRB Approval To Proceed With Compassionate Use Of Leronlimab For Patients With Triple-Negative Breast Cancer

VANCOUVER, Washington, Nov. 12, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...

CYDY - Wall Street Reporter presents: "NEXT SUPER STOCK Live!" Investor Conference November 14, 2019

NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Wall Street Reporter will be hosting the “NEXT SUPER STOCK - Live !” livestream online-only investor conference on Thursday, November 14, 2019 from 12:30PM-1:30PM EST. Registration is free. Click here to join: https://www.wallst...
CYDY - First Patient in CytoDyn's Triple-Negative Metastatic Breast Cancer Trial Shows Significant Reduction in Circulating Tumor Cells (CTC) and Reduced Tumor Size

VANCOUVER, Washington, Nov. 11, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...

CYDY - CytoDyn: When More Is Less

I first became interested in CytoDyn ( CYDY ) in February 2019. I was skeptical of its seemingly overblown claims and wrote an article for Seeking Alpha titled, " CytoDyn: What To Do When It's Too Good To Be True? ". As matters now stand, the situation seems dire. CytoDyn is pursuing too man...

CYDY - CytoDyn to Present at The MicroCap Rodeo Conference

VANCOUVER, Washington, Oct. 11, 2019 (GLOBE NEWSWIRE) --   CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indicatio...
Previous 10 Next 10